Tyler Drake, Adrienne Landsteiner, Lisa Langsetmo, Roderick MacDonald, Maylen Anthony, Caleb Kalinowski, Kristen Ullman, Charles J Billington, Anjum Kaka, Shahnaz Sultan, Timothy J Wilt
BACKGROUND: Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. PURPOSE: To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM). DATA SOURCES: MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023...
April 19, 2024: Annals of Internal Medicine